申请人李健是澳大利亚莫纳什大学药学研究所教授，是多黏菌素药理学研究领域和抗革兰氏阴性超级耐药菌新药研发的国际领头专家；是汤森路透2015高引用科学家以及2015全球最具影响力科学家之一。目前，共发表178篇SCI文章（多黏菌素相关135篇，近5年110篇），共引用6762次，h-因子达43。自2004年起已获得43项基金（总金额约3370万澳元，主持27项），包括6个NIH R01和1个R21基金（总金额约2440万美元，主持4项）。申请人是NIH多黏菌素研究组的重要成员，也是国际抗感染药理学会重要成员；曾担任第二届多黏菌素国际会议（美国）组委会主席；多次受邀主持美国ICAAC会议并作大会报告；是多个杂志的编委及86个国际期刊的特约审稿人。申请人所在莫纳什大学的研究团队有26人，包括微生物和细胞生物学，系统药理学，化学，体内药理和生物分析四个研究小组，旨在解决细菌耐药性的国际医学挑战。

The applicant – Dr Jian Li is a Professor at the Monash Institute of Pharmaceutical Sciences, Monash University, Austrilia. He is an international leader in the pharmacology of polymyxins (microbiology, chemistry, pharmacokinetics, pharmacodynamics and nephrotoxicity) and the discovery of novel antibiotics against Gram-negative ‘superbugs’. He is a Thomson Reuters 2015 Highly Cited Researchers (128 in total in Pharmacology & Toxicology) and listed in the 2015 World’s Most Influential Scientific Minds. Dr Li has 178 publications (110 since 2011) with 6,762 citations and an h-index of 43. His polymyxin research alone has led to 135 papers in high-calibre international journals, three book chapters and three patent applications. Since 2004 he has been awarded 43 grants (totally ~$33.7 M, 27 as CIA) including 6 R01 and one R21 projects by American National Institutes of Health (NIH, US$24.4 M, 4 as CIA). He is is a key member of the NIH Colistin Working Group and the Working Group of the International Society of Anti-infective Pharmacology (ISAP). He was the chair of the organising committee of the 2nd International Conference on Polymyxins (San Diego, 2015) and invited to chair polymyxin pharmacology symposia at the Interscience Conference and Antimicrobial Agents Chemotherapy (ICAAC). Dr Li is an editor and associated editor for two international journals, an editorial board member for five international journals, and an invited reviewer for 86 journals. Currently, his group has 26 people in four teams, Microbiology and Cell Biology, System Pharmacology, Chemistry, and Pharmacology and Bioanalysis. His research targets a significant global medical challenge, antimicrobial resistance.